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Abstract
Background: The growing tendency among opioid addicts to misuse multiple other drugs should
lead clinicians and researchers to search for new pharmacological strategies in order to prevent
life-threatening complications and minimize withdrawal symptoms during polydrug detoxification.
Methods: A non-randomised, open-label in-patient detoxification study was used to compare the
short-time efficacy of a standardised regimen comprising 6 days Buprenorphine and 10 days
Valproate (BPN/VPA) (n = 12) to a control group (n = 50) who took a 10-day traditional Clonidine/
Carbamazepine (CLN/CBZ) regimen. Sixty-two dependent subjects admitted to a detoxification
unit were included, all dependent on at least opioids and benzodiazepines. Other dependencies
were not excluded.
Results: In the BPN/VPA group, 8 out of 12 patients (67%) completed treatment compared with
25 of 50 patients (50%) in the CLN/CBZ group; this difference between the groups was non-
significant (p = 0.15). Withdrawal symptoms were reduced in both groups, but only the BPN/VPA
group achieved a reduction in withdrawal symptoms from day one. The difference between the two
groups was significantly in favour of the BPN/VPA group for days 2 (p < 0.001), 3 (p < 0.05), 4 (p
< 0.001), 5 (p < 0.01), 7 (p < 0.01) and 8 (p < 0.05). The BPN/VPA combination did not affect blood
pressure, pulse or liver function, and the total burden of side-effects was experienced as modest.
There appeared to be no pharmacological interactions of clinical concern, based on measurement
of Buprenorphine and Valproate serum levels. Both the patients and the staff were satisfied with
the standardised treatment combination.
Conclusion: Overall, the combination of Buprenorphine and Valproate seems to be a safe and
promising method for treating multiple drug withdrawal symptoms. The results of this study
suggest that the BPN/VPA combination is potentially a better detoxification treatment for polydrug
withdrawal than the traditional treatment with Clonidine and Carbamazepine. However, a
randomised, double-blind study with a larger sample size to confirm our results is recommended.
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Background
Withdrawal treatment appears to have no effect on long-
term abstinence, so detoxification should lead to more
definite drug-free treatment efforts. Nonetheless, detoxifi-
cation can be a major obstacle for some patients, and the
availability of managed and safe withdrawal is a prerequi-
site for long-term treatment.
There have been several studies on separate opioid or ben-
zodiazepine withdrawal treatments [1-6]. However, stud-
ies that focus on polydrug detoxification are scarce,
although benzodiazepine co-dependence is common in
opiate abuse [7-9]. Other substances of abuse including
stimulants, cannabis, hallucinogens and inhalants do not
require specific treatment in patients who are being
detoxified from sedative/hypnotics and/or opioids [10].
When opioid withdrawal is influenced by benzodiazepine
co-dependence and withdrawal, the detoxification proc-
ess becomes more complex with regard to both diagnosis
and treatment regimen.
De Wet et al. report that opioid and benzodiazepine with-
drawal syndromes have two distinct clinical symptoms/
pathways, driven by different neurobiological mecha-
nisms: noradrenergic activity in the locus coeruleus for
opioid withdrawal and γ-aminobutyric acid (GABA-ergic)
for benzodiazepine withdrawal [11]. However, there is a
substantial overlap between the two in terms of clinical
symptoms. These authors found that co-dependent
patients concurrently detoxified from benzodiazepines
and opioids reported more severe withdrawal symptoms
than those detoxified from opioids alone, and concurrent
benzodiazepine withdrawal exacerbated the opioid with-
drawal symptoms. Benzodiazepine withdrawal dimin-
ishes the inhibitory GABA-ergic input to the locus
coeruleus, hence the exacerbation.
There are traditionally two main regimens for opioid
detoxification. The first uses opioid agonists such as Meth-
adone (MET) or Buprenorphine (BPN) given in tapering
doses. A meta-analysis showed no significant differences
between BPN and MET in terms of retention in treatment
and completers, but symptoms may resolve more quickly
with BPN [12]. The second regimen uses non-opioids,
medications not involved in the misuse pattern. There has
been widespread use of α-adrenergic antagonists such as
Clonidine (CLN) because of their ability to reduce symp-
toms (e.g. tremor and restlessness) due to noradrenergic
hyperactivity. Treatment with CLN has been standard in
Scandinavia since 1980, mainly because there has been a
"system culture" of resistance to the use of opioids in
withdrawal regimes. However, studies that compare BPN
and CLN conclude that BPN is associated with fewer
adverse effects than CLN, and completion of withdrawal
treatment is significantly more likely with BPN [12,13].
Benzodiazepine withdrawal has traditionally been treated
by stepwise benzodiazepine (BZD) tapering or rapid dis-
continuation of BZD followed by symptom-reducing
medication using antiepileptics e.g. Carbamazepine
(CBZ) or Valproate (VPA). Zullino et al. showed that CBZ
had proved efficient in several studies [14]. However, CBZ
is a cyp 3A4 inducer that interacts with opioids such as
MET and BPN. An up to 60% reduction in serum Metha-
done level has been reported when combined with CBZ
[15,16]. Interaction of CBZ with the serum BPN level has
so far received less attention, but our clinical experience
has shown that this combination is troublesome.
In our clinical practice we have felt the need for a stand-
ardised and safe detoxification treatment regimen for our
drug addicts, as dependence on multiple drugs is so com-
mon. A standardised regimen is viewed as an improve-
ment over the previous practice of making individual
adjustments in supplementary therapy during detoxifica-
tion. The overall aim of this study was to establish a new
safer standard treatment without interaction problems.
VPA is theoretically a promising candidate for treating
sedative-hypnotic withdrawal because of its facilitating
actions on GABA levels and GABA-A receptor function
[17]. VPA does not interact with opioids and has shown
good results in alcohol withdrawal [18-21]. However,
studies of VPA in BZD withdrawal are scarce. Research has
shown that VPA 150–1200 mg/day reduced the intensity
of symptoms in protracted benzodiazepine withdrawal, as
well as acting as an anticonvulsant [22]. In contrast, Rick-
els et al. could not confirm the positive effect of VPA on
BZD withdrawal symptoms [23].
The objectives of the study were 1) to assess whether a
novel standardised treatment regimen – Buprenorphine
(BPN) combined with Valproate (VPA) – will result in
fewer withdrawal symptoms during detoxification of opi-
ate-polydrug users than the existing treatment regimen,
i.e. Clonidine (CLN) combined with Carbamazepine
(CBZ); 2) to determine whether there are differences in
treatment retention between the BPN/VPA and the CLN/
CBZ groups; and 3) to assess differences in clinical side-
effects and biochemical interactions between the two
treatment regimens.
Methods
Setting and participants
The study was conducted in an inpatient detoxification
unit. All eligible patients admitted between February and
November 2003 were invited to participate. Twelve
patients were included. Inclusion criteria were opiate and
benzodiazepine dependence according to the ICD-10
[24]. In addition, use of opioids and benzodiazepine was
verified by urine analysis. Exclusion criteria were severeBMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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mental illness, epilepsy and pregnancy. Co-dependence
on other drugs (e.g. alcohol, cannabis, amphetamine or
other stimulants) did not exclude individuals from partic-
ipation. Mean number of dependence diagnosis per
patient was 4.5 different drugs. The control group con-
sisted of 50 patients admitted for detoxification before
starting Medical-supported Maintenance Treatment
(MMT) in 2000–2002; these patients met the same inclu-
sion and exclusion criteria.
Ethics
The study was approved by the National Committees for
Research Ethics in Norway no. S-02165 and Norwegian
Medicines Agency no. 02-09435. All patients in the inter-
vention group gave written informed consent prior to
treatment.
Treatment regimens
Buprenorphine tablets (Subutex®) were administered sub-
lingually for the first 6 days. The daily dosages were 6, 8,
8, 4, 2 and 2 mg, the first four days being divided into two
daily doses.
Valproate (Orfiril long®) was given in dosage of 1200 mg,
divided in two daily doses from day 3 onward. The medi-
cation was terminated when the urine was free of opiates
and benzodiazepines.
The first dose of Buprenorphine was administered under
supervision when the patient had obvious abstinence
symptoms. The sublingual tablets were crushed to ensure
good absorption and compliance.
Control group (n = 50)
Carbamazepine (Tegretol®) tablets, 200 mg, 3 times daily
(600 mg) for 10 days. Clonidine (Catapresan®) tablets, 50
– 100 μg, 3 times daily (150 – 300 μg) for 10 days.
Measurements
Treatment retention
The primary outcome measure for determining the suc-
cess of the treatment was the proportion of patients who
were retained in treatment and followed the detoxifica-
tion schedule.
Questionnaires
The National Client Form for Addiction Treatment [25] was
administered prior to intervention to characterize the
study population along sociodemographic (e.g. educa-
tion, employment, social relation, housing), medical,
substance use and psychiatric domains.
The Subjective Opiate Withdrawal Scale (SOWS) [26] con-
tains 16 symptoms, the intensity of which the patient
rates on a scale of 0 (not at all) to 4 (extremely).
Nielsen's Benzodiazepine Withdrawal Symptom Form [27]
was created on the basis of eight European studies; it
measures abstinence symptoms during benzodiazepine
withdrawal. It consists of 25 items, and the patient reports
the intensity of the symptoms on a scale of 0 (not at all)
to 10 (extremely). The instrument is also validated to
measure changes in withdrawal symptoms during treat-
ment.
Biochemical
Urine drug screening
Urine samples were collected every second day. Urine
drug screening results (Rhode Diagnostika, type Micro
Screen Multi Drug Screen Cup) were coded qualitatively
as positive or negative for metabolites of illicit opioids
(cutoff = 300 ng/ml), benzodiazepine (cutoff = 200 ng/
ml), amphetamine (cutoff = 300 ng/ml and THC (cutoff =
20 ng/ml).
Blood analysis
Serum levels of Buprenorphine and Valproate were meas-
ured in the mornings, 12 h after administration, on days
3, 4 and 10, and analyses were conducted in the Depart-
ment for Clinical Pharmacology, St. Olavs Hospital,
Trondheim, using LC/MS.
Statistical analysis
The predetermined outcome measures were retention in
treatment and reduction in withdrawal symptoms
assessed by various rating scales. Retention in treatment
(number of days staying in treatment) was determined by
Kaplan-Meier survival analysis and a log rank test. Com-
parison between groups for SOWS was performed using
the Mann-Whitney U-test. We analysed the data using
SPSS for Windows, version 12.5.
Results
General characteristics
Table 1 shows the background characteristics of the two
groups. The control group (traditional treatment with
CLN/CBZ) had the same diagnosis as the test group and
had started using drugs at the same age, but was some-
what older and had a longer history of drug abuse, espe-
cially heroin and amphetamine. There were also fewer
women in the control group.
Treatment retention
Figure 1 shows the proportion of patients in the two
groups retained in treatment each day. Patients in the
CLN/CBZ-group were less likely to complete the medical
phase of detoxification than those in the BPN/VPA-group;
retentions at the end were 67% (8 of 12 patients) in the
BPN/VPA-group and 50% (25 of 50 patients) in the con-
trol group. The difference was not significant (p = 0.15,
Kaplan-Meier survival analysis and log rank test). In theBMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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BPN/VPA group only two patients terminated treatment
early. The reasons given were "craving" and restlessness.
One of them was detoxified from Methadone. He had
wrongly been given Buprenorphine too early, and this led
to greater withdrawal distress. Two patients left the ward
on day nine for unknown reasons. In the CLN/CBZ-
group, 40% (20) of the patients terminated early
(between days 3 and 6).
Reduction of withdrawal symptoms
Figure 2 shows the mean SOWS scores for the two groups
in a visual day by day comparison. Both combinations
showed reduced withdrawal symptoms, but only BPN/
VPA showed a reduction from the first day. The difference
was significant in favour of BPN/VPA for the first four days
and days seven and eight (Mann-Whitney U-test, p <
0.05). Withdrawal symptoms in the control group
increased from day two to four, before the symptom bur-
den decreased. Those who left treatment early did so dur-
ing the critical period when withdrawal symptoms were
most intense. About 40% had discontinued by day four in
the control group with CLN/CBZ.
For the BPN/VPA group, the Nielsen's Benzodiazepine With-
drawal Symptom Form showed a similarly good reduction
from day one, as did the SOWS score for this group. From
day one to day two the average score decreased from 80 to
40 points and thereafter decreased slowly, down to 5
points on day ten.
None of the patients in either group developed psychosis
or convulsions.
Safety evaluation
No serious adverse effects were reported by the BPN/VPA
group and none discontinued treatment owing to adverse
events. Mild discomfort from nausea was reported by two
persons during the treatment phase; nausea is a well-
known side-effect of Buprenorphine. Two patients in the
BPN/VPA group initially mentioned headache and four
reported sleep disturbance, which disappeared after two
or three days. These side-effects may also be due to
Buprenorphine. Sleep difficulties were treated with Alime-
nazin 20–40 mg or Trimipramin 25–50 mg. Drowsiness,
dry mouth and fall in blood pressure were commonly
reported in the CLN/CBZ group; blood pressure had to be
measured every day before and after the medications were
given, and the dose of Clonidine had to be regulated
owing to the lowered pressure. Daily measurements in the
BPN/VPA group showed that pulse and blood pressure
were stable (see Fig. 3). Overall, BPN/VPA had a better
adverse effect profile and was well tolerated by the
patients.
Laboratory tests
In the BPN/VPA group there was no change in haemo-
globin, leucocytes or C-reactive protein (CRP) during
treatment. Liver function tests (GT, AST and ALT)
improved slightly (mean GT from 50 U/l to 40 U/l, mean
AST from 67 U/l to 46 U/l and mean ALT from 93 U/l to
83 U/l).
Interaction study
Measurements of serum levels of Buprenorphine alone,
and the combination Buprenorphine/Valproate after
steady state, showed no interaction. The mean serum level
(± SD) of Buprenorphine 4 mg × 2 was 1.50 (± 0.55)
nmol/l, and for the combination 1.55 (± 0.35) nmol/l.
The mean serum Valproate level decreased by 26% from
512 (± 59) μmol/l for Valproate 600 mg × 2 alone to 367
(± 56) μmol/l for Valproate 600 mg × 2 combined with
Buprenorphine 4 mg × 2. We think this last finding is an
artefact and will offer an explanation in the discussion sec-
tion.
Discussion
The novel combination treatment, BPN/VPA, for opiate
dependents with polydrug use proved to be significantly
better than the previously established combination ther-
apy, CLN/CBZ, in terms of reduced withdrawal symptoms
during the observed 10-day detoxification period. Moreo-
ver, the BPN/VPA combination treatment did not involve
Table 1: Demographic data of patients treated with Buprenorphine/Valproate (BPN/VPA) n = 12, and Clonidine/Carbamazepine 
(CLN/CBZ) n = 50.
BPN/VPA – group CLN/CBZ – group
Gender: Male (%) 42% 76%
Mean age (range) 28 (21–41) 38 (26–44)
Substance use:
First time heroin use (mean age) 19 18
First time injected drugs (mean age) 20 18
Years of heroin use (mean years) 7 18
Years of BZD use (mean years) 13 19
Years of cannabis use (mean years) 14 22
Years of amphetamine use (mean years) 7 19BMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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pharmacological interactions between BPN and VPA, and
generally the therapy seemed to be safe, well tolerated and
free of severe side-effects. Our results also indicate,
although non-significantly, that retention in treatment
was improved in the BPN/VPA group, probably as a result
of the diminished total burden of withdrawal symptoms
especially during the first days of detoxification. An addi-
tional advantage of our suggested standardised regimen is
the cost-benefit aspect. Compared to BZD withdrawal
with tapering doses, as De Wet et al. described [11], our
regimen reduces the time needed for withdrawal treat-
ment.
Polydrug withdrawal treatment has scarcely been investi-
gated in the literature. However, careful examination of
the addiction monotherapy literature reveals that co-
dependency with other drugs is very common. For exam-
ple, in the large NIDA Clinical Trials Network that studied
13 days of Buprenorphine-Naloxone for opioid detoxifi-
cation, co-dependencies with cocaine, cannabis, alcohol
etc. were observed [28]. Supplementary medications were
widely used to manage anxiety and restlessness (e.g.
Oxazepam, Lorazepam, Phenobarbital and Hydroxyzine
HCl), bone pain and arthralgias (e.g. Methocarbamol,
Ibuprofen and Acetaminophen), nausea (e.g. Trimeth-
obenzamide), diarrhoea (e.g. Loperamide and Donnatal)
and insomnia (e.g. Zolpidem tartrate, Trazadone HCl,
Doxepin HCl and Diphenhydramine). Most (80.3%)
patients received at least one ancillary medication during
the study, but the authors did not use a standard regime
from the beginning.
A search of Medline and Cochrane Library using the key-
words "polydrug addiction", "multiple drug addiction",
"detoxification" and "withdrawal treatment" revealed
only two relevant studies; both were combination studies
from the same centre in Germany. Schneider et al. com-
pared BPN/CBZ with Oxazepam/CBZ and found better
retention rates in the BPN/CBZ group (73% vs. 67%) [29].
BPN/CBZ also resulted in a faster reduction of withdrawal
symptoms. Seifert et al. compared BPN/CBZ with MET/
CBZ and found best retention (71% vs. 42%) and propor-
Proportion of patients retained in treatment Figure 1
Proportion of patients retained in treatment. Kaplan-Meyer analysis. Log rank test p = 0.15. Buprenorphine/Valproate group 
(BPN/VPA) n = 12, and Clonidine/Carbamazepine group (CLN/CBZ) n = 50.BMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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tionally fewer withdrawal symptoms the first days of treat-
ment in the BPN/CBZ group [30]. These studies gave
retention rates similar to those in our study and support
our finding that BPN is the most suitable opioid agonist
for treating polydrug withdrawal. However, these authors
did not take into account the problem of interaction
between CBZ and opioids and they did not measure
serum levels, as we have done.
In our clinical practice most opioid-dependent patients
abuse benzodiazepines and other drugs such as CNS stim-
ulants and cannabis. Polydrug dependency complicates
the detoxification process. Monotherapy is often not suf-
ficient. A strict monotherapy approach (BPN or MET) also
exposes patients to possible life-threatening complica-
tions such as seizures etc. The medical combination BPN/
VPA has been our standard procedure since this clinical
study. The patients are satisfied and so are the members of
staff. For clinical practice one has to be aware of a slight
increase in withdrawal symptoms on day six, representing
the full breakthrough of benzodiazepine withdrawal
symptoms. The symptoms decrease from day seven with-
out supplementary medication; no one left treatment at
this stage. Valproate treatment incurs some risk of birth
defects (1 – 5% vs. 0,5 – 1% for Carbamazepine) [31]. We
therefore recommend a pregnancy test for fertile women
before the start and alternative treatment regimens for
pregnant patients.
The finding of reduced serum Valproate levels requires an
explanation. Buprenorphine has a half-life of 4 h; a stable
serum level is achieved on day two. The blood test is taken
on day three, i.e. after steady state. Both tests for
Buprenorphine are therefore conducted after steady state.
However, Valproate has a half-life of 16 h. Steady state
requires 4–5 days of treatment. The combined medicine
blood test was taken only 24 h after the first dose. Until
steady state, the serum level of Valproate will increase. We
therefore assume that the low serum level of Valproate
measured in this combination treatment does not indicate
Opiate Withdrawal Symptoms during treatment with Clonidine/Carbamazepine (CLN/CBZ) n = 50, and Buprenorphine/Val- proate (BPN/VPA) n = 12 Figure 2
Opiate Withdrawal Symptoms during treatment with Clonidine/Carbamazepine (CLN/CBZ) n = 50, and Buprenorphine/Val-
proate (BPN/VPA) n = 12. Mean change in SOWS score from baseline. Lower score indicates fewer withdrawal symptoms. * p 
< 0.05 versus CLN/CBZ. ** p < 0.01 versus CLN/CBZ. *** p < 0.001 versus CLN/CBZ.BMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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any interaction. It rather indicates that steady state had
not yet been achieved for VPA at the time of sampling.
This explanation is supported by serum level measure-
ments in a few of our patients who had a dual diagnosis
of epilepsy and opioid dependence: maintenance treat-
ment with Valproate and Buprenorphine led to no inter-
action with the serum level of Valproate.
Limitations
The small number of patients included in the BPN/VPA
treatment group limits the possibility of drawing firm
conclusions from this study. We compared the BPN/VPA
group with a historical control group of patients, and this
kind of comparison introduces methodological weak-
nesses. For example, there may have been different moti-
vations among the two groups. In addition, we showed
that the two groups did not match perfectly in certain gen-
eral characteristics (i.e. greater mean age and longer his-
tory of opiate abuse in the control group). Therefore these
results must be viewed with caution and should ideally
only be the precursor of a more detailed investigation,
preferably a randomised controlled trial.
Suggestions for future research
At the time of our study, it was reasonable to compare
Buprenorphine with the current standard practice for the
management of opioid withdrawal (CLN). However,
there is now clearer evidence that Buprenorphine is more
effective than Clonidine [12]. As for the adjunct medica-
tion for benzodiazepine withdrawal, Valproate was cho-
sen due to the expectations of less pharmacological
interaction with Buprenorphine.
Future research should aim to determine the additional
contribution of Valproate to the management of com-
bined opioid/benzodiazepine withdrawal. Our sugges-
tion for appropriate comparison in future randomised
controlled trials is to compare Buprenorphine alone with
Buprenorphine + Valproate. Because a number of coun-
tries have Diazepam in tapering doses as a standard
approach to benzodiazepine withdrawal, it would also be
an alternative to include Buprenorphine + Diazepam in
the comparison.
Conclusion
The novel combination treatment, BPN/VPA, for opiate
dependents with polydrug use proved to be significantly
better than the previously established combination ther-
Daily measurement of blood pressure and pulse for the Buprenorphine/Valproate group (n = 12) Figure 3
Daily measurement of blood pressure and pulse for the Buprenorphine/Valproate group (n = 12).BMC Psychiatry 2006, 6:54 http://www.biomedcentral.com/1471-244X/6/54
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apy, CLN/CBZ. Overall, the results indicate that BPN/VPA
combination therapy is a promising, effective and safe
standard treatment regimen for detoxification of opiate-
dominated polydrug users. A more detailed evaluation of
this new combination treatment is required before a gen-
eral recommendation can be made. However, in our clinic
we have already adapted this standardised BPN/VPA treat-
ment regimen as the treatment of choice when opioid and
benzodiazepine dependence has been verified.
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